Voglibose 0.30 mg + Glimepiride 2.00 mg + Metformin Hydrochloride 500.00 mg

GLIMISAVE MV 2mg | 0.3mg is a fixed-dose combination medication that contains Voglibose, Metformin Hydrochloride, and Glimepiride. Voglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by delaying the digestion of carbohydrates. Metformin Hydrochloride is a biguanide that improves insulin sensitivity and reduces hepatic glucose production. Glimepiride is a sulfonylurea that stimulates the release of insulin from the pancreas. Together, these three components work synergistically to lower blood sugar levels and improve glycemic control in patients with type 2 diabetes mellitus. GLIMISAVE MV 2mg | 0.3mg helps regulate blood glucose levels, reduces the risk of complications associated with diabetes, and enhances overall glycemic management.

Take GLIMISAVE MV 2mg | 0.3mg orally with meals, as directed by your doctor. The dosage and frequency of administration will depend on your individual medical condition and response to treatment. It is important to follow the prescribed regimen and not exceed the recommended dosage.

Allopathic

The contents and information provided here are solely intended to provide a general overview of the products and medicines and must be used for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. The information contained herein should not be used as a substitute for the advice of a qualified physician. For all queries or doubts related to your medical condition, we highly recommend that you consult your registered medical practitioner.